Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polycythemia vera with uncommon presentations

Ayse P Dincer1, Seshan Subramanian, Musaberk Goksel

  • 1Mercy Hospital and Medical Center, Chicago, IL 60616, USA.

Clinical Advances in Hematology & Oncology : H&O
|November 1, 2005
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

The Lancet. Oncology·2021
Same author

Reply.

The journal of allergy and clinical immunology. In practice·2016
Same author

Successful rapid desensitization to intravenous etoposide using a 14-step protocol.

The journal of allergy and clinical immunology. In practice·2015
Same author

Sodium-wasting nephropathy caused by cisplatin in esophageal cancer.

The journal of supportive oncology·2008
Same author

A case of tubulointerstitial nephritis and uveitis in an adult male.

International urology and nephrology·2005
Same author

Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization.

Journal of pediatric hematology/oncology·2004
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles